Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

Future Medicinal Chemistry
Douglas S JohnsonBenjamin F Cravatt

Abstract

This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase. Covalent inhibitors have many desirable features, including increased biochemical efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compound. Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s). Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo. For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent. These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets. The substantial number of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of ...Continue Reading

References

Jun 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·R R YocumJ L Strominger
Aug 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·G J RothP W Majerus
Aug 1, 1986·Journal of Medicinal Chemistry·P LindbergB Wallmark
Oct 1, 1965·Proceedings of the National Academy of Sciences of the United States of America·D J Tipper, J L Strominger
Aug 1, 1980·European Journal of Biochemistry·F J Van Der OuderaaD A Van Dorp
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·Y LiuB F Cravatt
Apr 13, 2001·Biochemistry·D KiddB F Cravatt
Jul 2, 2002·Nature Biotechnology·Gregory C AdamBenjamin F Cravatt
Jul 4, 2002·Molecular & Cellular Proteomics : MCP·Doron GreenbaumMatthew Bogyo
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Jean-Marie PereilloClaudine Picard
Oct 22, 2002·Nature Structural Biology·Daniel Lim, Natalie C J Strynadka
Oct 29, 2002·Chemistry & Biology·Anna BorodovskyBenedikt M Kessler
Dec 12, 2002·Chemical Reviews·James C PowersKaren Ellis James
Jan 2, 2003·Nature Reviews. Drug Discovery·Deepak L Bhatt, Eric J Topol
Feb 4, 2003·Nature Reviews. Drug Discovery·Lars OlbePer Lindberg
Apr 17, 2003·Journal of the American Chemical Society·Anna E SpeersBenjamin F Cravatt
May 13, 2003·Nature Biotechnology·Donmienne LeungBenjamin F Cravatt
Nov 5, 2003·Nature Reviews. Neuroscience·Daniele Piomelli
Dec 18, 2003·Drug Discovery Today·Hartmuth C Kolb, K Barry Sharpless
May 5, 2004·Chemistry & Biology·Anna E Speers, Benjamin F Cravatt
Jun 24, 2004·Journal of the American Chemical Society·Jai Moo ShinGeorge Sachs
Jun 29, 2004·Proceedings of the National Academy of Sciences of the United States of America·Alan SaghatelianBenjamin F Cravatt
Jul 2, 2004·The Journal of Pharmacology and Experimental Therapeutics·Aron H LichtmanBenjamin F Cravatt
Sep 2, 2004·Nature Reviews. Drug Discovery·David C Swinney
Oct 7, 2004·Angewandte Chemie·David J Vocadlo, Carolyn R Bertozzi
Nov 4, 2004·Journal of the American Chemical Society·Elaine W S ChanShao Q Yao
Mar 8, 2005·Drug Metabolism Reviews·Shufeng ZhouYu-Zong Chen
Apr 13, 2005·Biochemistry·James G Robertson
May 18, 2005·Proceedings of the National Academy of Sciences of the United States of America·Eunice L KwakDaniel A Haber
Jun 15, 2005·Annual Review of Biochemistry·Michele K McKinney, Benjamin F Cravatt
Jun 25, 2005·Current Drug Metabolism·Amit S KalgutkarShawn P Harriman
Aug 25, 2005·Nature Methods·Nadim JessaniBenjamin F Cravatt
Sep 1, 2005·Current Opinion in Microbiology·Mark S WilkeNatalie C J Strynadka

❮ Previous
Next ❯

Citations

Aug 4, 2012·ACS Chemical Neuroscience·Micah J NiphakisBenjamin F Cravatt
Mar 28, 2013·Chemical Reviews·Prakasam ThirumuruganKrzysztof Jozwiak
Apr 19, 2013·Journal of Medicinal Chemistry·Sarah E PoplawskiWilliam W Bachovchin
Apr 2, 2011·Nature Reviews. Drug Discovery·Juswinder SinghAdrian Whitty
Jun 28, 2011·Nature Reviews. Drug Discovery·David C Swinney, Jason Anthony
Jan 4, 2012·Nature Reviews. Drug Discovery·Daniel A Bachovchin, Benjamin F Cravatt
Mar 24, 2011·Future Medicinal Chemistry·Jonathan B Baell
Dec 22, 2012·Future Medicinal Chemistry·Gino D'Oca, Isaac Bruce
Dec 14, 2012·Future Medicinal Chemistry·Sumit S MahajanAdam R Renslo
Mar 19, 2014·European Journal of Medicinal Chemistry·Tamar TraubeAmnon Albeck
Oct 8, 2014·Pharmaceutical Patent Analyst·Adam M Gilbert
Oct 21, 2014·Future Medicinal Chemistry·Jamal El BakaliRebecca Deprez-Poulain
May 17, 2011·Nature Chemical Biology·Alexander AdibekianBenjamin F Cravatt
Mar 28, 2012·International Reviews of Immunology·Bruno CenniMarie Gottar-Guillier
May 12, 2015·Expert Opinion on Drug Discovery·Hongyu Zhao, Justin Dietrich
Jan 13, 2016·Expert Opinion on Drug Discovery·Adebayo A AdeniyiMahmoud E S Soliman
Jul 10, 2012·Expert Opinion on Drug Metabolism & Toxicology·Jonathan MoggsSalah-Dine Chibout
May 23, 2012·Expert Opinion on Drug Discovery·Amit S Kalgutkar, Deepak K Dalvie
Feb 14, 2016·Plant & Cell Physiology·Kyoko Morimoto, Renier A L van der Hoorn
Jan 27, 2015·Organic & Biomolecular Chemistry·Hannelore RückerSabine Amslinger
Dec 23, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Vadim Bernard-GauthierRalf Schirrmacher
Jun 25, 2015·Protein Science : a Publication of the Protein Society·Giulia BiancoArthur J Olson
Nov 26, 2015·ChemMedChem·Concepción González-Bello
Jun 6, 2014·ACS Medicinal Chemistry Letters·Thuy NguyenKeith C Ellis
May 23, 2014·Journal of the American Chemical Society·Jennifer L FurmanChan Hyuk Kim
Sep 16, 2014·ACS Medicinal Chemistry Letters·Steven M MossKenneth A Jacobson
Oct 22, 2014·Journal of Medicinal Chemistry·Cornelius KlöckChaitan Khosla
Nov 26, 2015·Future Medicinal Chemistry·Concepción González-Bello
Oct 10, 2013·Chemistry : a European Journal·Nafisah Al-RifaiSabine Amslinger
Oct 16, 2015·Rapid Communications in Mass Spectrometry : RCM·T Eric BallardAlfin D N Vaz
Aug 14, 2015·Journal of the American Chemical Society·Heather E MurreyDouglas S Johnson
Jan 22, 2015·Chemistry : a European Journal·Georg C RudolfStephan A Sieber
Dec 10, 2014·Journal of Medicinal Chemistry·Xiao TanMichèle Reboud-Ravaux
Aug 26, 2014·Journal of Medicinal Chemistry·Christian JöstChristian D Klein
Jun 9, 2015·Chemistry & Biology·Jing LuCraig M Crews
Feb 27, 2013·Chemistry & Biology·Qingsong LiuNathanael S Gray
Dec 10, 2013·Bioorganic & Medicinal Chemistry Letters·Robert MahCynthia M Shafer

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nature Reviews. Drug Discovery
J SinghAdrian Whitty
Journal of Medicinal Chemistry
Michele H Potashman, Mark E Duggan
Current Opinion in Chemical Biology
J SinghArthur F Kluge
© 2021 Meta ULC. All rights reserved